Behandling av myelom när högdoskemoterapi inte är möjlig. Nya läkemedel - alternativ för äldre patienter
Engelsk titel: Treatment of myeloma when high dose therapy is not possible. New drugs - alternative for elderly patients
Läs online
Författare:
Mellstedt, Håkan
;
Gimsing, Peter
;
Waage, Anders
Email: hakan.mellstedt@karolinska.se
Språk: Swe
Antal referenser: 20
Dokumenttyp:
Översikt
UI-nummer: 11101146
Sammanfattning
Myeloma patients above the year of 65 are generally not eligible for high dose therapy and stem cell transplantation. There has been a significant improvement in the prognosis for myeloma patients below the age of 65 but so far not for elderly patients. The introduction of the novel anti-myeloma drugs thalidomide, bortezomib and lenalidomide has significantly added to the prognosis of young patients. Theses drugs have now also been shown in clinical studies to dramatically improve the prognosis for myeloma patients more than 65 years not eligible for high dose chemotherapy. With the introduction of these drugs the overall response rate, progression free survival and overall survival can be expected to rise significantly. Toxicity is acceptable. The International Myeloma Working Group 2009 guidelines recommend thalidomide, bortezomib and lenalidomide for front-line as well as for relapsed/refractory disease treatment.